Tyme Technologies

TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tyme Technologies, Inc. (TYME) CEO Steve Hoffman on Q2 2020 Results - Earnings Call Transcript

NEW YORK, Sept.  30, 2019  (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging overall (OS) results and has a well-tolerated safety profile. TYME also announced encouraging Quality of Life data for this challenging patient population. The supporting data from the study were presented at the European Society of Medical Oncology Congress (ESMO) being held on September 27- October 1, 2019 in Barcelona, Spain. As a result of these clinical outcomes, TYME recently launched the multi-center randomized controlled pivotal stage of the TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer.

TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

Tyme Technologies has several pending events that could inject some positive momentum into the stock. One of these is the final Phase II data for the TYME-88-PANC study at ESMO.

Tyme To Go For A Run Into ESMO Data

NEW YORK, Sept.  17, 2019  (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019. The Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advancements in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, and sarcoma cancers.

Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

As of late, it has definitely been a great time to be an investor Tyme Technologies.

Will Tyme Technologies Continue to Surge Higher?

NEW YORK, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright in New York City on Monday, September 9, 2019. The Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.

Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019

Tyme Technologies utilizes its Cancer Metabolism-Based Therapies ((CMBTs)) to treat cancers with a huge unmet medical need.

Tyme Technologies: Multiple Catalysts Expected In 2nd Half 2019 To Get Ball Rolling

Today, we take a look at a small oncology firm called Tyme Technologies, which appears to be a $1 "Lottery Ticket" at current trading levels.

Tyme Technologies: A $1 'Lottery Ticket' Worthy Of Consideration

Tyme Technologies recently reported positive data for a Phase II study involving its SM-88 product candidate in advanced pancreatic cancer. As a result, the stock went up ~30%.

Tyme Technologies: Debating An Investment After Recent SM-88 Update

In the latest Tyme Technologies news, TYME stock is up over 20% following a positive data regarding the company's pancreatic cancer treatment.
The post Tyme Technologies News: Why TYME Stock Is Rocketing appeared first on InvestorPlace.

Tyme Technologies News: Why TYME Stock Is Rocketing

Shares of Tyme Technologies Inc.  shot up 31% in active morning trading Friday, after the biotechnology company provided upbeat updated data from its phase 2 study of SM-88 for the treatment of pancreatic cancer.

Tyme Technologies stock soars on heavy volume after upbeat update to cancer treatment study

Chewy

Vistra Energy

According to GuruFocus Insider Data, the recent CFO buys were: Vistra Energy Corp, Chewy Inc. and Tyme Technologies Inc.

Weekly CFO Buys Highlight: Jun 23

Tyme Technologies, Inc.'s (TYME) CEO Steve Hoffman on Q4 2019 Results - Earnings Call Transcript

News for Tyme Technologies Stock (TYME)